Navigation Links
Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
Date:12/22/2008

At the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies in Las Vegas, Zannos Grekos, MD, director of Cardiac and Vascular Disease for Regenocyte Therapeutic (www.regenocyte.com), addressed physicians from around the world with a presentation on patients treated with pre-engineered Adult Stem Cells. In the presentation, Grekos showed the successful engraftment of stem cells into damaged organs and subsequent regeneration of tissue. The clinical success has spurred a project entailing growing organs for transplant from patients’ own stem cells using technology developed by National Aeronautic Space Association (NASA). In describing details of the stem cells project Grekos stated, “This is the logical next step in harnessing the regenerative power of stem cells. This will be the next phase in turning science into medicine.”

LAS VEGAS, Nev. (Business Wire EON) December 22, 2008 -- The presentation also cited stem cells treatment results at one month through one year follow up. The Regenocyte team of international scientists and physicians have been treating cardiac, vascular, pulmonary, and kidney diseases, with plans next year to accept patients suffering from macular degeneration and neurological diseases.

Athina Kyritsis, MD, chair of Regenocyte's Medical Advisory Committee, explains "the findings presented today are based on several years of Regenocyte's clinical experience using Autologous Adult Stem Cell Therapy. I believe we have only begun to discover what Adult Stem Cells can accomplish in altering the course of diseases currently believed to be untreatable with not only improved clinical results, but also a financial savings to society."

  • Grekos also highlighted several case studies to illustrate his team's success with Adult Stem Cells. According to their findings, cardiac disease patients experience an average increase of 21% in ejection rates as well as measurable improvements in congestive heart failure class status, some in as little as one month post-treatment. "We are able to bring patients from a Class IV congestive heart failure status to a Class II status in less than 180 days," said Grekos. Regenocyte Therapeutic's clinical data from PET scans confirm that Adult Stem Cells have the ability to engraft themselves into areas damaged by myocardial infarction (heart attacks) and turn into viable new heart muscle. "Three months after treatment, cardiac nuclear scans of the areas treated reveal reversal of damage. We have been able to take patients off the transplant list, and we have been doing it consistently."

Most recently, physicians at the Dominican Republic division of Regenocyte announced clinical results of a 46-year-old patient with pulmonary hypertension who was treated with Adult Stem Cells. His pulmonary artery mean pressure went from 41mmHg (severe pulmonary hypertension) to 24 mmHg (normal) in six months. The patient's saturations are now consistently high and he no longer needs to be supplemented with oxygen continuously or considered for a lung transplant. Another patient was successfully treated for cardiac sequelae of Fabry's Disease, and is also no longer considered for heart transplant.

Hector Rosario, MD, chief of Interventional Cardiology for the Dominican Republic division of Regenocyte, is thrilled with the clinical outcomes to date. "It is personally very gratifying to alter the prognosis in patients who have exhausted all other options," Rosario says. Leonel Francisco Liriano, MD, professor of medicine at Pontifical Catholic University School of Medicine and medical director of the Regenocyte Dominican Republic division added that "patient safety is always paramount. We're achieving these results with a treatment that poses minimal risk, much lower than traditional surgical procedures."

Regenocyte Therapeutic is currently using Adult Stem Cells Therapy to treat Congestive Heart Failure, Cardiomyopathy, Peripheral Artery Disease, Coronary Artery Disease, Kidney Disease, Ischemic Heart Disease, Pulmonary diseases (COPD, Pulmonary Fibrosis, and Pulmonary Hypertension) and Early Senile Dementia. Patients can call 866-216-5710 or visit www.regenocyte.com for information or consultation.

Read the full story at http://www.prweb.com/releases/adult_stem/stem_cells/prweb1786234.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Brain cells work differently than previously thought
3. Embryonic Stem Cells Repair Human Heart
4. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
5. Circulating fats kill transplanted pancreas cells, study shows
6. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
7. Melanoma drug revs immune cells but cancer cells ignore it
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Embryonic stem cells used to grow cartilage
10. Molecular probe paints cancer cells in living animals, Stanford researchers find
11. USC researcher identifies stem cells in tendons that regenerate tissue in animal model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, a hippie ... chemical-laden beauty products, one company is going against the norm with a line of ... rising star in the green space is proud to announce its latest retail partnership ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... HealthPostures, ergonomics ... Angle chair , furniture that may support women during pregnancy. Potential benefits of using ... feet, improved rest and comfort and healthier levels of sitting and standing. , Need ...
(Date:5/25/2016)... ... ... The United States Food and Drug Administration (FDA) has now cleared Capillus® ... date, the company is the first and only manufacturer of low level laser therapy ... alopecia. , “This new level of clearance substantiates what many physicians have experienced ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... a Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider ... delivery system accelerates with the implementation of MACRA, we believe that continuing to ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Furthering its position ... athletics, The National Center for Drug Free Sport (Drug Free Sport®) is excited to ... conference, to be held July 12 – 13 in Kansas City, MO, will gather ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: